Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2026-07-28

Clinical Trial Results: Siplizumab in T1DM [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating siplizumab in type 1 diabetes mellitus was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Siplizumab (siplizumab)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Type 1 Diabetes Mellitus | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2026-07-28